REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to rescue patients from Hard-to-Treat lymphoma
Disease control TerminatedThis phase II trial tests a two-step approach for people with relapsed or refractory large B-cell lymphoma who are eligible for a stem cell transplant. First, patients receive tafasitamab (an antibody) plus lenalidomide, followed by tafasitamab combined with ICE chemotherapy. The…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to outsmart Hard-to-Treat lymphoma
Disease control OngoingThis phase 2 trial tests a combination of two drugs—TTI-622 and pembrolizumab (Keytruda)—in about 10 adults with diffuse large B-cell lymphoma that has come back or not responded to treatment. TTI-622 blocks a protein called CD47 that cancer cells use to hide from the immune syst…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC